Skip to content
Bored Studies
RecruitingPhase 3

52-week Open Label Safety-Tolerability Study

LB Pharmaceuticals Inc. · NCT07369154

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–65 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
900
US sites recruiting
23
Study start
April 23, 2026
Record last updated
September 9, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Phase 3, open label, multicenter study designed to assess the long term safety and tolerability of LB-102 for the treatment of adult patients with stable schizophrenia

Being studied: LB-102

Conditions: Schizophrenia

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Provide ICF
  • Patients clinically stable PANSS \</= 80 at screening
  • CGI-S \</+ 3 at screening
  • Medically stable
  • BMI 18 -40
  • Taking oral antipsychotic treatment for at least 30 days
  • Have stable living environment

Exclusion Criteria

  • Sexually active M/F patients not willing to use highly effective contraception
  • Breast feeding
  • History of treatment resistance to schizophrenia medications
  • DSM-5 current diagnosis other than schizophrenia
  • Risk of suicidal behavior
  • History or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, or oncologic disease or any other

Recruiting US locations

  • Chandler Clinical Trials

    Chandler, AZ 85224

    Site contact: Anna Mangus · 480-716-4590 · amangus@chandlertrials.com

  • Pillar Clinical Research

    Bentonville, AR 72712

    Site contact: Nicole Gutierrez · 479-367-2688 · ngutierrez@pillarhc.com

  • Pillar Clinical Research

    Little Rock, AR 72204

    Site contact: Nichole Gutierrez · 501-307-1919 · ngutierrez@pillarhc.com

  • Woodland International Research Group

    Little Rock, AR 72211

    Site contact: Ashley Poole · 501-221-8681 · apoole@ergclinical.com

  • Advanced Research Center

    Anaheim, CA 92805

    Site contact: Halynn Nguyen · 714-999-6688 · hnguyen@arctrials.com

  • Synapse Clinical Trials

    Cerritos, CA 90703

    Site contact: Paige Mansfield · 949-350-0492 · p.mansfield@synapsetrials.com

  • ProScience Research Group

    Culver City, CA 90230

    Site contact: Paola Aguirre · 424-227-8127 · paola.aguirre@proscienceerg.com

  • CenExel

    Culver City, CA 92845

    Site contact: Dakota Gainers · 714-943-5874 · d.gainers@cenexel.com

  • Synergy San Diego

    San Diego, CA 92064

    Site contact: Corey Weise · 619-303-6130 · cweise@ergclinical.com

  • CenExel

    Hollywood, FL 33024

    Site contact: Anna Molero · 954-990-7649 · a.molero@cenexel.com

  • Segal Trials

    Miami Lakes, FL 33063

    Site contact: Melissa Rodco · 305-722-8444 · mrodco@segaltrials.com

  • Health Synergy Clinical Research

    West Palm Beach, FL 33407

    Site contact: Katherine Grigelis · 561-473-3472 · kat@hscresearch.com

  • CenExel

    Atlanta, GA 30331

    Site contact: Amber Tannahill · 404-881-5800 · a.tannahill@cenexel.com

  • Accelerated Clinical Trial

    Snellville, GA 30078

    Site contact: Alexis Melson · 678-255-1041 · amelson@acceleratedclinicaltrials.org

  • Pillar Clinical Research

    Chicago, IL 60641

    Site contact: Nichole Gutierrez · 479-367-2688 · ngutierrez@pillarhc.com

  • CenExel Gaithersburg

    Gaithersburg, MD 20877

    Site contact: Evan Covington · 301-251-4702 · e.covington@cenexel.com

  • Arch Clinical Trials

    St Louis, MO 63141

    Site contact: Israa Diab · 314-266-1243 · idiab@archclinicaltrials.com

  • Redbird Research

    Las Vegas, NV 89119

    Site contact: Pamela Pioquinto · 702-577-200 · pamela@redbird-research.com

  • Neuro-Behavioral Clinical Research

    New York, NY 11516

    Site contact: Cameron Anthony · 516-295-7230 · canthony@NBReasearch.com

  • Neuro-Behavioral Clinical Research

    Canton, OH 44720

    Site contact: Crystal Blackford · 330-493-1118 · cblackford@nb-cr.com

  • Adams Clinical

    Philadelphia, PA 19104

    Site contact: Cassie Blanchard · 267-207-2511 · cblanchard@adamsclinical.com

  • Adams Clinical

    DeSoto, TX 75115

    Site contact: Ben Kurian, MD, MPH · 972-544-6121 · bkurian@adamsclinical.com

  • Pillar Clinical Research

    Richardson, TX 75080

    Site contact: Scott Bartley, MD · 214-396-4844 · studies@pillarhc.com

Study contacts (from the official record)

  • Branislav Mancevski, MD · 212-605-0300 · clinicaltrials@lbpharma.us
All mental health studies in Arizona →
52-week Open Label Safety-Tolerability Study (NCT07369154) | Bored Studies